Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate ihl-42x

New york and melbourne, australia, july 30, 2024 (globe newswire) -- incannex healthcare inc. (nasdaq: ixhl), (‘incannex' or the ‘company'), a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic-assisted psychotherapies, is pleased to announce that it has completed participant dosing in the ihl-42x bioavailability/bioequivalence (ba/be) clinical trial.
IXHL Ratings Summary
IXHL Quant Ranking